Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. is a phase 3, randomised interventional study registered as NCT05918302 by Grupo Espanol de Tumores Neuroendocrinos, with a registry enrolment figure of 170 participants, started 2023-10-27 and due to reach its primary completion in 2029-03. Interventions recorded: 177Lu-edotreotide; Everolimus. Conditions listed: Neuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: "Patients who have histologically confirmed metastatic or locally advanced unresectable well/moderately differentiated; World Health Organization (WHO\]) 2015 criteria; neuroendocrine tumor of lung (typical and atypical carcinoids) or thymus origin either functioning or non-functioning". Sites: Belgium, France, Italy, Spain. No results are recorded here; the registry entry is the source.